🇺🇸 FDA
Patent

US 8663635

N-cadherin: target for cancer diagnosis and therapy

granted A61KA61K2039/505A61P

Quick answer

US patent 8663635 (N-cadherin: target for cancer diagnosis and therapy) held by The Regents of the University of California expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61P, A61P13/08, A61P35/00